	US 12,295,951 B2
	Compounds for use in a method of treating or preventing neurological and/or psychiatric disorders
Sidarta Ribeiro, Natal-NR (BR); and Amanda Feilding, Oxford (GB)
Assigned to The Beckley Foundation, Oxford (GB)
Appl. No. 17/631,876
Filed by The Beckley Foundation, Oxford (GB); D'Or Institute for Research and Education—IDOR, Botafogo-RJ (BR); and Universidade Federal do Rio Grande do Norte, Natal-RN (BR)
PCT Filed Jul. 30, 2020, PCT No. PCT/EP2020/071525 § 371(c)(1), (2) Date Jan. 31, 2022, PCT Pub. No. WO2021/019023, PCT Pub. Date Feb. 4, 2021.
Claims priority of application No. 1911024 (GB), filed on Aug. 1, 2019.
Prior Publication US 2022/0273644 A1, Sep. 1, 2022
Int. Cl. A61K 31/48 (2006.01); A61K 45/06 (2006.01); A61P 25/16 (2006.01); A61P 25/22 (2006.01); A61P 25/28 (2006.01); A61P 25/36 (2006.01)

CPC A61K 31/48 (2013.01) [A61K 45/06 (2013.01); A61P 25/28 (2018.01); A61P 25/16 (2018.01); A61P 25/22 (2018.01); A61P 25/36 (2018.01)]

20 Claims

1. A method of treating, preventing, reducing the symptoms of, or slowing the progression of a neurological and/or psychiatric disorder in a subject, comprising:

a. administering to the subject a therapeutically effective amount of a lysergamide, or a pharmaceutically acceptable salt thereof; and

b. providing the subject with a cognitive training.